Back to top

Analyst Blog

Agilent Inc. (A - Analyst Report) signed an exclusive agreement with Switzerland based company Roche Holding AG (RHHBY - Analyst Report) to facilitate the transition of Roche’s NimbleGen microarray customers to Agilent’s microarray platform. Roche will be exiting the array market and is phasing out its array production and services.

It is expected that the similarity of products and services provided by the two companies will make the transition smooth and easy for Roche’s end users.

The NimbleGen microarrays from Roche are currently used in researches done on DNA, protein, tissues, antibodies and other substances.

Roche Holding is a veteran in the pharmaceuticals and diagnostics markets. Therefore, like Agilent, it also supplies test kits and instruments to various ongoing researchers worldwide. This is a positive for Agilent, which will now be able to tap some of its customers.

The agreement is testimony to Agilent’s product breadth and the flexibility of its solutions. The company has been strengthening its position in the bioanalytical testing segment with successive acquisitions. It appears that this strategy is paying off, as it is resulting in important deal wins that are helping it expand into an important and fast-growing segment.

Agilent’s revenue in the third quarter was flat sequentially and up 1.9% year over year, short of management’s expectations of a 2-3% sequential increase ($1.77 billion to $1.79 billion). The Electronic Measurement segment contributed 49.0% of revenue. The weakness was on the computing/semiconductor sides of the business.

The Life Sciences segment generated 23.0% of revenue, down 1.0% sequentially and up 2.1% from last year. The Chemical Analysis segment generated 22.0% of third quarter revenue, down 8.8% sequentially and 7.0% year over year. The sequential decline was largely because of weakness in food testing.

Currently, Agilent Technologies has a Zacks #4 Rank, implying a short-term Sell rating and Roche Holding a Zacks Rank of #2, implying a short-term Buy rating.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 116.37 +7.72%
CHYRONHEGO… CHYR 2.72 +5.84%
US SILICA H… SLCA 70.72 +4.00%
MALLINCKROD… MNK 80.11 +2.32%
RF MICRO DE… RFMD 11.76 +2.31%